Wide Ranks

ALLO

Allogene Therapeutics, Inc.

2.50

Top Statistics
Market Cap 524 M Forward PE -2.72 Revenue Growth 0.00 %
Current Ratio 9.35 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.27 Enterprise / Revenue 7561.40 Price To Sales Trailing12 Months 12190.23
Profitability
Profit Margins 0.00 % Operating Margins -625246.50 %
Balance Sheet
Total Cash 291 M Total Cash Per Share 1.39 Total Debt 92 M
Total Debt To Equity 19.95 Current Ratio 9.35 Book Value Per Share 2.21
All Measures
Short Ratio 1497.00 % Message Board Id finmb_558022022 Shares Short Prior Month 39 M
Return On Equity -0.5415 City South San Francisco Uuid 074a6d28-e148-3d16-a323-524e6da42340
Previous Close 2.52 First Trade Date Epoch Utc 1 B Book Value 2.21
Beta 0.8360 Total Debt 92 M Volume 2 M
Price To Book 1.13 Fifty Two Week Low 1.99 Total Cash Per Share 1.39
Total Revenue 43000 Shares Short Previous Month Date 1 B Target Median Price 9.00
Audit Risk 9 Max Age 86400 Recommendation Mean 1.78
Sand P52 Week Change 0.3133 Operating Margins -625246.50 % Target Mean Price 9.04
Net Income To Common -283428992 Short Percent Of Float 0.2350 Implied Shares Outstanding 209 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 2 M
Average Volume10days 2 M Total Cash 291 M Next Fiscal Year End 1 B
Held Percent Insiders 0.1743 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Share Holder Rights Risk 7 Regular Market Previous Close 2.52
Target Low Price 3.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.66
Open 2.53 Free Cashflow -111507504 State CA
Dividend Yield 0.00 % Return On Assets -0.2582 Time Zone Short Name EST
Board Risk 7 Trailing Eps -1.55 Day Low 2.48
Address1 210 East Grand Avenue Shares Outstanding 209 M Compensation Risk 10
Price Hint 4 Target High Price 14.00 Website https://www.allogene.com
52 Week Change 0.0638 Average Volume 2 M Forward Eps -1.39
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 903.80 %
Is_sp_500 False Regular Market Day High 2.62 Profit Margins 0.00 %
Debt To Equity 19.95 Fifty Two Week High 5.78 Day High 2.62
Shares Short 35 M Regular Market Open 2.53 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 7561.40 Revenue Growth 0.00 %
Shares Percent Shares Out 0.1672 Operating Cashflow -217308992 Currency USD
Time Zone Full Name America/New_York Market Cap 524 M Is_nasdaq_100 False
Zip 94080 Quote Type EQUITY Industry Biotechnology
Long Name Allogene Therapeutics, Inc. Overall Risk 10 Regular Market Day Low 2.48
Held Percent Institutions 0.8025 Current Price 2.50 Enterprise To Ebitda -1.27
Financial Currency USD Current Ratio 9.35 Industry Disp Biotechnology
Number Of Analyst Opinions 12 Country United States Float Shares 151 M
Two Hundred Day Average 3.08 Governance Epoch Date 1 B Enterprise Value 325 M
Price To Sales Trailing12 Months 12190.23 Forward PE -2.72 Regular Market Volume 2 M
Ebitda -254972992 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer.

It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia.

In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.

2 for the treatment of gastric and pancreatic cancer.

The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.

A.

; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3.

The company was incorporated in 2017 and is headquartered in South San Francisco, California.